阅读说明：本技术 消化道肿瘤标记物检测的引物探针组、试剂盒及其应用 (Primer probe set and kit for detecting digestive tract tumor marker and application of primer probe set and kit ) 是由 赵国栋 于 2020-07-10 设计创作，主要内容包括：本发明公开了一种消化道肿瘤标记物,所述标记物为甲基化的CLIP4基因,存在至少1个修饰的CpG位点,本发明还公开了一种消化道肿瘤标记物检测的引物探针组及试剂盒,所述的引物探针组序列上包含至少1个可以与修饰CPG位点互补配对的碱基位点。本发明对消化道恶性肿瘤高危人群和患者的生物样本中的特异性DNA甲基化标记物CLIP4基因检测,可以为消化道恶性肿瘤的早期筛查、早期诊断及个性化治疗提供一种高灵敏度且非侵入性的检测手段。(The invention discloses a digestive tract tumor marker, which is a methylated CLIP4 gene and has at least 1 modified CpG site, and also discloses a primer probe set and a kit for detecting the digestive tract tumor marker, wherein the sequence of the primer probe set comprises at least 1 base site which can be complementarily paired with the modified CPG site. The invention can detect the CLIP4 gene of the specificity DNA methylation marker in the biological samples of the high risk group and the patients of the alimentary tract malignant tumor, and can provide a high-sensitivity and non-invasive detection means for the early screening, the early diagnosis and the personalized treatment of the alimentary tract malignant tumor.)

1. The digestive tract tumor marker is characterized in that the marker is a methylated CLIP4 gene, at least 1 modified CpG site exists, and the nucleotide sequence of the CLIP4 gene is shown as SEQ ID No.1 or SEQ ID No. 2.

2. The gut tumor marker of claim 1, wherein the modification comprises the conversion of cytosine to 5-methylcytosine catalyzed by DNA methyltransferase.

3. The primer probe set for detecting the digestive tract tumor marker of claim 1, wherein the sequence of the primer probe set comprises at least 1 base site which can be complementarily paired with the modified CPG site, and the sequence of the primer probe set comprises any one or more of the following groups:

primer probe set 1: SEQ ID NO.3, SEQ ID NO.4 and SEQ ID NO. 5;

primer probe set 2: SEQ ID NO.6, SEQ ID NO.7 and SEQ ID NO. 8;

primer probe set 3: SEQ ID NO.9, SEQ ID NO.10 and SEQ ID NO. 11;

primer probe set 4: SEQ ID NO.12, SEQ ID NO.13 and SEQ ID NO. 14;

primer probe set 5: SEQ ID NO.15, SEQ ID NO.16 and SEQ ID NO. 17;

primer probe set 6: SEQ ID NO.18, SEQ ID NO.19 and SEQ ID NO. 20.

4. A kit for detecting a marker for a tumor in the digestive tract, said kit comprising the primer probe set of claim 3.

5. The kit for detecting the digestive tract tumor marker according to claim 4, which is characterized by further comprising a primer probe set of an internal reference gene ACTB, wherein the sequence of the primer probe set of the internal reference gene ACTB is shown as SEQ ID No.21, SEQ ID No.22 and SEQ ID No. 23.

6. Use of the kit according to claim 4 or 5 for the early diagnosis and screening of digestive tract malignancies and their precancerous lesions.

7. Use according to claim 6, characterized in that it comprises:

extracting DNA from a human biological sample;

converting the extracted DNA to bisulfite and unmethylated cytosine C to uracil U;

performing a methylation real-time fluorescent quantitative PCR reaction by using the kit of claim 4 or 5;

and judging whether the patient has the digestive tract tumor or not according to the Ct value of the CLIP4 gene.

8. The use of claim 7, wherein the methylation real-time fluorescence quantitative PCR reaction is performed under the following conditions:

the first stage is as follows: (95 ℃ for 15-30min) x 1 cycle;

and a second stage: (95 ℃ for 10s, 55-60 ℃ for 30s, 72 ℃ for 10-15s) x 50 cycles;

and a third stage: (40 ℃ C. for 1 min). times.1 cycle.

9. The use of claim 7, wherein the Ct value of the CLIP4 gene is determined by:

a. the positive external quality control detection result is positive,

b. the negative external quality control detection result is negative,

c. ACTB signals can be detected in all biological samples, and the Ct value is less than or equal to 40,

d. after meeting the above standard, the samples are judged according to Ct value, average value or effective reaction number of CLIP 4.

10. The use of claim 7, wherein the human biological sample comprises one or more of blood, stool, saliva, sputum, urine, tissue; the digestive tract tumor comprises one or more of gastric cancer, stomach atypical hyperplasia, gastric adenoma, colorectal cancer, colorectal atypical hyperplasia and colorectal adenoma.

Technical Field

The invention relates to a primer probe set for detecting a digestive tract tumor marker, a kit and application thereof, belonging to the technical field of biological medicines.

Background

According to the latest malignant tumor morbidity and mortality data published by the World Health Organization (WHO), 4,285,033 new malignant tumor cases and 2,865,174 death cases are shown in 2018 in China. The digestive tract malignant tumors (colorectal cancer, gastric cancer, liver cancer, esophageal cancer and pancreatic cancer) are ranked within the top ten in the morbidity and mortality of all malignant tumors, the morbidity and mortality of gastric cancer and esophageal cancer in China occupy more than 50% of the global morbidity and mortality in the global range, and the morbidity of colorectal cancer also shows a gradually rising trend in China. Therefore, the malignant tumor of the digestive tract is the most common malignant tumor category which endangers the health of residents in China at present.

In China, all digestive tract tumors show the phenomenon of low early diagnosis and early treatment rate, and early diagnosis and early treatment of digestive tract malignant tumors are not realized, so that the method is an important reason for high morbidity and mortality of the digestive tract malignant tumors in China. The gold standard for early diagnosis of digestive tract tumors is endoscopic detection. The endoscope detection has the advantages of high accuracy and strong specificity, and can directly observe the focus position and carry out biopsy. However, endoscopic detection methods have a number of drawbacks: 1. due to the traditional concept, insufficient cognition which brings benefits to endoscope screening by people, low consciousness of early diagnosis and early treatment and great worry about discomfort brought by endoscope examination, the willingness of residents to participate in endoscope screening is low; 2. at present, government-oriented endoscope free screening projects are tried in high-risk groups in regions with high incidence of malignant tumors in a small part of alimentary tracts in China, endoscope screening is not brought into the government medical insurance payment range in most regions, China is still a developing country, even in rural regions such as Jiangsu, developed provinces, endoscope screening still has high cost for ordinary families, and the positivity of residents for actively seeking endoscope screening is limited. 3. The endoscope screening needs a plurality of conditions such as endoscope doctors with abundant experience, expensive endoscope equipment, perfect endoscope cleaning and disinfecting facilities and the like, so that in a country with a large population, due to the lack of necessary medical and sanitary resources and manpower resources of the endoscope doctors, convenient endoscope screening cannot be realized, and the difficulty is particularly prominent in regions with laggard economic development level. Meanwhile, most of the hospital endoscopy needs to be reserved in advance, is time-consuming and labor-consuming, and also limits the endoscopy to become a first-line digestive tract malignant tumor screening means. 4. Endoscopic screening, as an invasive screening means, requires preparation in advance, such as taking cathartics or narcotics, is painful during the detection process, and is less acceptable for Chinese people who have a strong traditional concept and who invade privacy. However, some other existing protein tumor markers such as CEA and CA199 can only detect a small part of late-stage cancers, have a detection rate of less than 30% for early-stage cancers and canceration, and cannot be used for early-stage screening of digestive tract malignant tumors at all. However, the number of people needing early screening of the digestive tract in China is nearly 8 hundred million (>40 years), and even 5% of people who really participate in early screening do not exist, which means that early diagnosis and early treatment of digestive tract tumors in China still face huge challenges, and at the same time means that the early diagnosis and early treatment of digestive tract tumors in China are a market with the level of hundreds of millions and urgent needs to be developed and outbreak.

Disclosure of Invention

The invention aims to overcome the defects of the prior art and provides a primer probe set and a kit for detecting a digestive tract tumor marker and application thereof.

In order to solve the technical problems, the invention provides a marker for digestive tract tumor, wherein the marker is methylated CLIP4 gene, at least 1 modified CpG site exists, and the nucleotide sequence of the CLIP4 gene is shown as SEQ ID No.1 or SEQ ID No. 2.

Preferably, the modification comprises the conversion of cytosine to 5-methylcytosine catalyzed by DNA methyltransferase.

The invention also provides a primer probe group for detecting the digestive tract tumor marker, wherein the sequence of the primer probe group comprises at least 1 base site which can be complementarily paired with the modified CPG site, and the sequence of the primer probe group is any one or more of the following groups:

primer probe set 1: SEQ ID NO.3, SEQ ID NO.4 and SEQ ID NO. 5;

primer probe set 2: SEQ ID NO.6, SEQ ID NO.7 and SEQ ID NO. 8;

primer probe set 3: SEQ ID NO.9, SEQ ID NO.10 and SEQ ID NO. 11;

primer probe set 4: SEQ ID NO.12, SEQ ID NO.13 and SEQ ID NO. 14;

primer probe set 5: SEQ ID NO.15, SEQ ID NO.16 and SEQ ID NO. 17;

primer probe set 6: SEQ ID NO.18, SEQ ID NO.19 and SEQ ID NO. 20.

The invention also provides a kit for detecting the digestive tract tumor marker, which comprises the primer probe set.

Preferably, the kit further comprises a primer probe set of the internal reference gene ACTB, and the sequences of the primer probe set of the internal reference gene ACTB are shown as SEQ ID No.21, SEQ ID No.22 and SEQ ID No. 23.

The invention also discloses the application of the kit in early diagnosis and screening of malignant tumors and precancerous lesions of the digestive tract, which comprises the following steps:

extracting DNA from a human biological sample;

converting the extracted DNA to bisulfite and unmethylated cytosine C to uracil U;

carrying out methylation real-time fluorescence quantitative PCR reaction by using the kit;

and judging whether the patient has the digestive tract tumor or not according to the Ct value of the CLIP4 gene.

Preferably, the methylation real-time fluorescence quantitative PCR reaction conditions are as follows:

the first stage is as follows: (95 ℃ for 15-30min) x 1 cycle;

and a second stage: (95 ℃ for 10s, 55-60 ℃ for 30s, 72 ℃ for 10-15s) x 50 cycles;

and a third stage: (40 ℃ C. for 1 min). times.1 cycle.

Preferably, the method for performing interpretation according to the Ct value of the CLIP4 gene comprises the following steps:

a. the positive external quality control detection result is positive,

b. the negative external quality control detection result is negative,

c. ACTB signals can be detected in all biological samples, and the Ct value is less than or equal to 40,

d. after meeting the above standard, the samples are judged according to Ct value, average value or effective reaction number of CLIP 4.

Preferably, the human biological sample comprises one or more of blood, feces, saliva, sputum, urine, and tissue; the digestive tract tumor comprises one or more of gastric cancer, stomach atypical hyperplasia, gastric adenoma, colorectal cancer, colorectal atypical hyperplasia and colorectal adenoma.

The invention achieves the following beneficial effects: the invention can detect the CLIP4 gene of the specificity DNA methylation marker in the biological samples of the high risk group and the patients of the alimentary tract malignant tumor, and can provide a high-sensitivity and non-invasive detection means for the early screening, the early diagnosis and the personalized treatment of the alimentary tract malignant tumor.

Drawings

FIG. 1 is a genomic DNA amplification curve for detecting transformed colorectal-progressing adenoma, colorectal cancer and gastric cancer after transformation using the primer probe and the kit of example 1 of the present invention;

FIG. 2 shows the results of the primer probe combination kit of example 2 of the present invention for detecting colorectal cancer and tissues adjacent to colorectal cancer;

FIG. 3 shows the results of the primer probe combination kit for detecting colorectal cancer and tissues beside colorectal cancer in example 3 of the present invention;

FIG. 4 shows the results of detecting gastric cancer and tissues beside cancer by using the primer probe combination kit of example 4 of the present invention;

FIG. 5 is a ROC curve for colorectal cancer and normal control samples tested in example 5 of the present invention.

Detailed Description

The invention is further described below. The following examples are only for illustrating the technical solutions of the present invention more clearly, and the protection scope of the present invention is not limited thereby.